FilingsTodayMadrigal Pharmaceuticals
At a glance
Madrigal Pharmaceuticals reported 2025 revenue of $958.4M, up 432.1% from $180.1M in 2024. Operating margin was -31.3%. 2025 was the highest revenue year in this period. The company posted a loss in 2021, 2022, 2023, 2024 and 2025.
In the last 12 months 9 insiders reported 0 open-market purchases and 28 sales ($81.5M). 15 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $13.7M by Director Paul A Friedman on Dec 12, 2025.
Madrigal Pharmaceuticals filed 9 current reports (Form 8-K) in the last 12 months, most often for officer or director change (4), results of operations (4), shareholder vote results (1) and material agreement (1). The latest officer or director change was reported on Aug 12, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.
1 of the 20 investors tracked here held Madrigal Pharmaceuticals at the last quarter end, worth $24.7M combined. It is the largest weight for Renaissance Technologies (0% of its portfolio). Reduced: Renaissance Technologies.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$241.8M | -$295.3M | -$373.6M | -$465.9M | -$288.3M |
| Diluted EPS | $-14.63 | $-17.23 | $-17.33 | $-17.31 | $-10.15 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined